DE60127954D1 - Rekombinante oder gereinigte polyklonale antikörper zur behandlung den allergien - Google Patents

Rekombinante oder gereinigte polyklonale antikörper zur behandlung den allergien

Info

Publication number
DE60127954D1
DE60127954D1 DE60127954T DE60127954T DE60127954D1 DE 60127954 D1 DE60127954 D1 DE 60127954D1 DE 60127954 T DE60127954 T DE 60127954T DE 60127954 T DE60127954 T DE 60127954T DE 60127954 D1 DE60127954 D1 DE 60127954D1
Authority
DE
Germany
Prior art keywords
grass
allergen
pollen
polyclonal antibody
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60127954T
Other languages
English (en)
Other versions
DE60127954T2 (de
Inventor
John S Haurum
Kirsten Drejer
Ulrik Gregers Moerch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Symphogen AS
Original Assignee
Symphogen AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphogen AS filed Critical Symphogen AS
Application granted granted Critical
Publication of DE60127954D1 publication Critical patent/DE60127954D1/de
Publication of DE60127954T2 publication Critical patent/DE60127954T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE60127954T 2000-05-26 2001-05-25 Rekombinante oder gereinigte polyklonale antikörper zur behandlung den allergien Expired - Lifetime DE60127954T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DK200000839 2000-05-26
DKPA200000839 2000-05-26
US21198100P 2000-06-16 2000-06-16
US211981P 2000-06-16
PCT/DK2001/000365 WO2001089563A1 (en) 2000-05-26 2001-05-25 Recombinant or purified polyclonal antibodies for treating allergy

Publications (2)

Publication Number Publication Date
DE60127954D1 true DE60127954D1 (de) 2007-05-31
DE60127954T2 DE60127954T2 (de) 2008-01-17

Family

ID=26068829

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60127954T Expired - Lifetime DE60127954T2 (de) 2000-05-26 2001-05-25 Rekombinante oder gereinigte polyklonale antikörper zur behandlung den allergien

Country Status (13)

Country Link
EP (1) EP1283720B1 (de)
JP (1) JP2003534290A (de)
KR (1) KR100831118B1 (de)
CN (1) CN1437482A (de)
AT (1) ATE359819T1 (de)
AU (2) AU6206701A (de)
CA (1) CA2410586C (de)
DE (1) DE60127954T2 (de)
DK (1) DK1283720T3 (de)
ES (1) ES2282256T3 (de)
HK (1) HK1052305B (de)
NZ (1) NZ522605A (de)
WO (1) WO2001089563A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003041731A2 (en) * 2001-11-13 2003-05-22 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Method to obtain protection against bystander allergen
CN100383244C (zh) * 2003-01-07 2008-04-23 西福根有限公司 用于生产重组多克隆蛋白质的方法
CA2512647C (en) * 2003-01-07 2013-10-08 Symphogen A/S Method for manufacturing recombinant polyclonal proteins
TWI333977B (en) * 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
EP1758558B1 (de) 2004-05-12 2013-10-16 Baxter International Inc. Oligonucleotid-haltige mikrokügelchen; ihre verwendung zur herstellung eines medikaments zur behandlung von diabetes typ 1
AU2005244840C1 (en) 2004-05-12 2012-05-10 Baxter Healthcare S.A. Microspheres comprising protein and showing injectability at high concentrations of said agent
DE602005009954D1 (de) 2004-05-12 2008-11-06 Baxter Int Nukleinsäure-mikrokügelchen, ihre herstellung und abgabe
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
EP1771483A1 (de) 2004-07-20 2007-04-11 Symphogen A/S Rekombinanter polyklonaler anti-rhesus-d-antikörper und herstellungsverfahren
ATE548657T1 (de) 2004-07-20 2012-03-15 Symphogen As Prozedur zur strukturellen charakterisierung rekombinanter polyclonaler proteine oder einer polyclonalen zelllinie
MX2009001226A (es) 2006-08-04 2009-03-20 Baxter Int Composicion basada en microesferas para prevenir y/o revertir la diabetes autoinmune de nuevo inicio.
TW200846362A (en) * 2007-02-09 2008-12-01 Symphogen As A polyclonal antibody product
ES2369946T3 (es) 2007-03-01 2011-12-09 Symphogen A/S Procedimiento para clonación de anticuerpos análogos.
WO2008131129A2 (en) 2007-04-17 2008-10-30 Baxter International Inc. Nucleic acid microparticles for pulmonary delivery
CA2722348A1 (en) * 2008-04-23 2009-10-29 Symphogen A/S Methods for manufacturing a polyclonal protein
KR101242797B1 (ko) * 2010-06-08 2013-03-12 아주대학교산학협력단 락토페린 발현 수준 측정 제재를 포함하는 알러지성 비염 진단용 조성물
KR101803187B1 (ko) 2015-05-20 2017-12-01 중앙대학교 산학협력단 돼지풀 추출물을 유효성분으로 함유하는 IL-1β 관련질환 예방 또는 치료용 약학조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
US4740371A (en) * 1984-09-17 1988-04-26 International Institute Of Cellular And Molecular Pathology Treatment of allergy
CA1336818C (en) * 1987-04-16 1995-08-29 International Institute Of Cellular And Molecular Pathology Treatment of allergy and composition thereof
US5512283A (en) * 1990-07-06 1996-04-30 Allergene, Inc. Methods for the selective suppression of an immune response to dust mite der Pi
WO1994014475A1 (en) 1992-12-21 1994-07-07 Tanox Biosystems, Inc. ALLERGEN-SPECIFIC IgA MONOCLONAL ANTIBODIES AND RELATED PRODUCTS FOR ALLERGY TREATMENT
WO1995020401A1 (en) * 1994-01-31 1995-08-03 Trustees Of Boston University Polyclonal antibody libraries
US20030175277A1 (en) * 1996-09-11 2003-09-18 Elizabeth Shanahan-Prendergast Therapeutic formulations containing venom or venom anti-serum either alone or in combination for the therapeutic prophylaxis and therapy of neoplasms

Also Published As

Publication number Publication date
EP1283720B1 (de) 2007-04-18
ATE359819T1 (de) 2007-05-15
AU6206701A (en) 2001-12-03
DE60127954T2 (de) 2008-01-17
HK1052305A1 (en) 2003-09-11
EP1283720A1 (de) 2003-02-19
CA2410586C (en) 2010-07-20
HK1052305B (zh) 2007-10-12
ES2282256T3 (es) 2007-10-16
NZ522605A (en) 2005-03-24
WO2001089563A1 (en) 2001-11-29
AU2001262067B2 (en) 2005-09-29
JP2003534290A (ja) 2003-11-18
KR100831118B1 (ko) 2008-05-20
KR20030022134A (ko) 2003-03-15
DK1283720T3 (da) 2007-08-13
CA2410586A1 (en) 2001-11-29
CN1437482A (zh) 2003-08-20

Similar Documents

Publication Publication Date Title
DE60127954D1 (de) Rekombinante oder gereinigte polyklonale antikörper zur behandlung den allergien
Flicker et al. Renaissance of the blocking antibody concept in type I allergy
Holtfreter et al. Towards the immune proteome of Staphylococcus aureus–The anti-S. aureus antibody response
Choi et al. Bee pollen-induced anaphylaxis: a case report and literature review
Flicker et al. Passive immunization with allergen-specific IgG antibodies for treatment and prevention of allergy
ATE499112T1 (de) Immunologische verwendungen von immunmodulatorischen verbindungen für einen impfstoff und therapie gegen infektionskrankheiten
Jaligama et al. Regulatory T cells and IL10 suppress pulmonary host defense during early-life exposure to radical containing combustion derived ultrafine particulate matter
DK3626819T3 (da) Transgen mus, som producerer hybrid-antistoffer indeholdende humane variable områder og konstante områder fra mus
DE122009000019I1 (de) Rekombinierte humane antikörper gegen den humanen interleukin-6 rezeptor
WO2002005630A3 (en) Drug delivery device for animals
DE69636278D1 (de) Inhibitor des muskelproteinabbaus enthaltend einen il-6 rezeptor antikörper
PH12012501089A1 (en) Therapeutic human anti-il-1r1 monoclonal antibody
CA2519408A1 (en) High concentration antibody and protein formulations
Gokmen et al. Desensitization effect of preseasonal seven-injection allergoid immunotherapy with olive pollen on basophil activation: the efficacy of olive pollen-specific preseasonal allergoid immunotherapy on basophils
US7156099B1 (en) Nostril filtering system
Crawley et al. Control of immunoglobulin isotype production by porcine B-cells cultured with cytokines
WO2006009525A3 (en) P. aeruginosa mucoid exopolysaccharide specific binding peptides
Nygaard et al. The allergy adjuvant effect of particles–genetic factors influence antibody and cytokine responses
Neimert‐Andersson et al. Carbohydrate‐based particles reduce allergic inflammation in a mouse model for cat allergy
Masuyama et al. Guiding principles of sublingual immunotherapy for allergic rhinitis in Japanese patients
WO2021195385A8 (en) HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
ATE327252T1 (de) Verfahren zur identifizierung modifizierter rekombinanter graminaenpollen-allergene
Reginald et al. Different modes of IgE binding to CD23 revealed with major birch allergen, Bet v 1‐specific monoclonal IgE
GEP20063774B (en) Blocking Monoclonal Antibody to VLA-1 and Its Use for Treatment of Inflammatory Disorders
Huang et al. Induction of specific Th1 responses and suppression of IgE antibody formation by vaccination with plasmid DNA encoding Cyn d 1

Legal Events

Date Code Title Description
8364 No opposition during term of opposition